Case Report

Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib

Diego Márquez-Medina, Ariadna Gasol-Cudós, M. Teresa Taberner-Bonastre, Juan Carlos Samamé Pérez-Vargas, Antonieta Salud-Salvia, Antonio Llombart-Cussac

A Service de Oncología Médica, Hospital Universitari Arnau de Vilanova, Lleida, Spain
b Service de Oncología Médica, Hospital Universitari Arnau de Vilanova, Valencia, Spain

A R T I C L E   I N F O

Article history:
Received 1 January 2012
Accepted 2 April 2012
Available online 9 February 2013

Keywords:
Epidemiology
Erlotinib
Human papillomavirus
Non-small-cell lung cancer
Epidermal growth factor receptor mutations

A B S T R A C T

It has been suggested that human papillomavirus (HPV) could participate in the development of non-small-cell lung cancer (NSCLC). A higher HPV infection rate has been reported in the NSCLC samples from Asian non-smoker patients, with adenocarcinomas or responders to EGFR tyrosine kinase inhibitors (EGFR-TKI). We explored a potential relationship between EGFR mutation, response to EGFR-TKI and HPV infection in Western NSCLC patients. We retrospectively analyzed 40 NSCLC samples and the impact of age, gender, histology, tobacco habit and sample type. HPV infection rate was 2.5% and it was not statistically modified by any analyzed variable, although the limited sample size did not provide definitive conclusions. The rate of HPV infection in NSCLC should be studied in patients with EGFR mutations or a tendency toward presenting them.

© 2012 SEPAR. Published by Elsevier España, S.L. All rights reserved.

Virus del papiloma humano en cáncer de pulmón no microcítico. Impacto de mutaciones del EGFR o respuesta a erlotinib

R E S U M E N

Se ha sugerido que el virus del papiloma humano (HPV) puede originar cáncer de pulmón no microcítico (NSCLC). La tasa de infección HPV es mayor en NSCLC de asiáticos, no fumadores, con adenocarcinoma o respuesta a inhibidores tirosín-cinasa del receptor del factor de crecimiento epidermico (EGFR-TKI). Hemos explorado retrospectivamente la relación entre mutaciones EGFR o respuesta a EGFR-TKI e infección HPV en 40 pacientes con NSCLC, considerando el impacto del sexo, edad, subtipo histológico, tabaquismo y tipo de muestra. La tasa de infección HPV fue 2.5%, y no influyó ninguna variable analizada, aunque el escaso tamaño muestral no permite conclusiones definitivas. La tasa de infección HPV en NSCLC debería revisarse en pacientes con mutaciones EGFR o tendencia a presentarlas.

© 2012 SEPAR. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Introduction

Non-small-cell lung cancer (NSCLC) is the most frequent and lethal tumor in our setting. Tobacco smoke is the cause of more than 90% of cases, but it also appears in unexposed. This implicates the existence of other etiologic factors. In 1979, Syrjänen suggested that human papillomavirus (HPV) DNA, associated with the development of other cancers, could participate in the development of NSCLC.

The rate of HPV infection in NSCLC depends on multiple variables and can increase with the response to Gefitinib, an endothelial growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) mainly active in mutated EGFR. The relationship between HPV infection and the presence of EGFR mutations in NSCLC has never been researched, although both phenomena coincide in similar patients: Asians, women, non-smokers, those with adenocarcinomas (ADC) and Gefitinib responders. In order to explore this possibility and to confirm the viability of the project and that the initial results support those in the literature, we retrospectively analyzed 40
NSCLC samples treated in our center between April/2004 and September/2010.

**Clinical Observations**

Our series (Table 1) includes 20 males and 20 females, all Caucasian and aged 38–80. Thirteen were smokers, 2 smoked fewer than 5 cigarettes/day, 7 were ex-smokers and 20 were never-smokers. The samples were 12 biopsies in paraffin, 14 cell buttons obtained by fine-needle aspiration (FNA) and preserved in paraffin and 14 cytology samples obtained by FNA. We had 5 squamous carcinomas, 23 ADC, 4 ADC with bronchioloalveolar carcinoma (BAC) and 8 unspecified NSCLC. The EGFR status was unknown for 6 samples, 23 had native EGFR and 11 sensitizing mutations: 9 e19[p.746-750del], 1 e19(L747-A750del Plns), 1 e19(L746-A752del Vlns), 1 e19(c.2240-2257del), 1 e18(p.G719R), 1e18(E709A; G719R), 1e18(E709G) and e21(L858R) and 1 e21 (L858R). No resistance mutations were detected.² Twenty-eight cases received Erlotinib, another EGFR-TKI that is more effective on mutated EGFR.

DNA of the samples was extracted with DNeasy tissue kit (Qiagen GMBH, Hilden, Germany) and 37 HPV genotypes were amplified (including 13 varieties with high oncogenicity) with the Linear Array HPV genotyping test (Roche, Switzerland). We assessed the impact of several variables on the rate of HPV infection with either the Fisher or Chi-squared tests.

The incidence of HPV infection in the series was limited. It was detected in 1 out of 40 samples (62-year-old woman, non-smoker, with lung ADC and areas of BAC, native EGFR, responsive to Erlotinib for 7 months). No variables influenced the percentage of infection, although this is conditioned by the size of the series (Table 1). Neither sex (0% males vs 5% females, P=0.31) nor age (younger or older than 65, P=0.26) showed an influence. There were no differences among smokers, mild-smokers, ex-smokers or non-smokers (P=0.56), between biopsy, cell button or cytology (P=0.36) or between squamous-cell carcinomas, ADC with or without BAC or NSCLC without defined histology (P=0.1). There were no differences between samples with EGFR mutation, native EGFR or unstudied (P=0.68), or related with response (P=0.66) or progression-free survival with Erlotinib (P=0.93). The limited sample could not confirm differences between response to Erlotinib of NSCLC with the mutation or without it.

**Discussion**

The main limitation of our study is the small sample size (N=40) that does not allow us to draw conclusions about the incidence and association of HPV infection in NSCLC in a Mediterranean population. But our objective was merely to explore the association between HPV infection and presence of EGFR mutations, validate the technique and verify whether the preliminary data supported reports in the literature in order to extend the series in future research. Meanwhile, this and other manuscripts with a similar or smaller number of cases³–⁵ spark discussion and are the first to directly analyze the relationship between Erlotinib sensitivity, presence of EGFR mutations and HPV infection in NSCLC.

HPV infection in NSCLC depends on geographic area. A meta-analysis of 37 studies⁶ (N=24355) situates its incidence between 1% and 78.3%, with a mean of 7.1% in western countries and 20.4% in Asia. Another meta-analysis⁷ (N=4508) reduces the global rate of infection from 24.5% to 16% in Europe and North America and increases it to 35.7% in Asia. The low rate of HPV infection (0.5%) described in 399 Italian patients with NSCLC⁸ coincides with ours (2.5%), although this would need to be confirmed in more patients.

---

**Table 1**

<table>
<thead>
<tr>
<th>Variables of Our Sample</th>
<th>HPV Infection in NSCLC Samples According to the Varieties of Our Sample</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>20–39 (range 11–80)</td>
<td>0.051</td>
</tr>
<tr>
<td>Smoking</td>
<td>Never-smokers 20 (50)</td>
<td>0.056</td>
</tr>
<tr>
<td>Cell button</td>
<td>62 (38–80)</td>
<td>0.060</td>
</tr>
<tr>
<td>FNA</td>
<td>5 (2.5%)</td>
<td>0.400</td>
</tr>
<tr>
<td>Biopsy</td>
<td>23 (14–35)</td>
<td>0.450</td>
</tr>
<tr>
<td>Progression-free survival</td>
<td>Erlotinib P=0.929</td>
<td>0.480</td>
</tr>
<tr>
<td>Response to Erlotinib</td>
<td>5 (0%)</td>
<td>0.560</td>
</tr>
<tr>
<td>BAC adeno carcinoma with areas of bronchioloalveolar carcinoma</td>
<td>Erlotinib P=0.629</td>
<td>0.660</td>
</tr>
<tr>
<td>EGFR mutation</td>
<td>3 (1%)</td>
<td>0.780</td>
</tr>
<tr>
<td>Native EGFR</td>
<td>37 (94%)</td>
<td>0.860</td>
</tr>
<tr>
<td>Resistance to Erlotinib</td>
<td>5 (0%)</td>
<td>0.930</td>
</tr>
</tbody>
</table>
HPV infection also depends on the sample analyzed. A Canadian study (No.=1241) and a Croatian study (No.=84) also found no differences between NSCLC and healthy control subjects when comparing bronchial suction or serum samples, but there was evidence of difference in the biopsies. Two Italian studies\(^8,11\) reported infection rates of 21% and 14%, respectively, when they analyzed 21 paraffin blocks and 95 fresh samples of NSCLC. And the Health Institute in Rome\(^12\) reported 21.7% HPV infection in 2468 NSCLC biopsies.

HPV is found in tumor cells and not in healthy neighboring cells,\(^13\) and it is therefore more difficult to find evidence of its DNA in bronchial suction or serum samples with less tumor cellularity. Although all our samples presented tumors, there were no differences between biopsies, cell buttons and cytology samples.

Differences have been reported in HPV infection according to NSCLC histology. A Polish article\(^14\) found no differences between 22 squamous-cell carcinomas, 13 ADC and 5 large-cell carcinomas; meanwhile, a French paper\(^15\) reports a greater incidence of ADC in 31 frozen samples (11% vs 25%). In Asia, a Japanese study\(^5\) with 36 NSCLC observed no differences between squamous carcinomas and ADC (10% vs 9%); a Chinese study\(^16\) with 72 squamous-cell carcinomas, 37 ADC and 71 healthy control subjects found more HPV in squamous-cell carcinoma (51%, 16%, and 22%, respectively); another Japanese article\(^5\) found more HPV in ADC than in squamous carcinomas (30% vs 7%; \(P=0.044\)) and in other studies,\(^17,18\) it is 2.3 times higher in women, non-smokers and ADC. In Asian studies,\(^13,19\) HPV infection in NSCLC is higher in women (57.6% vs 41.1%, \(P=0.048\)) and non-smokers (10.12%, higher).

For the first time, our study probes the possibility that HPV infection is more frequent in patients with EGFR mutation or those who are sensitive to Erlotinib. It has been published that HPV infection increases in NSCLC patients responders to Gefitinib\(^3\) (75% vs 0%) and this mainly acts on mutated EGFR. The most frequent EGFR mutations are in women, Asians, non-smokers and those with ADC, which is the population with greater incidence of HPV.

**Conclusion**

Our data do not confirm the relationship between HPV infection in NSCLC and presence of EGFR mutations or response to Erlotinib. Nevertheless, the determination technique is viable and this hypothesis merits further research with a more extensive series.

**Conflict of Interests**

The authors declare having no conflicts of interest.

**References**